Journal article
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, S Coutre, CS Tam, SP Mulligan, U Jaeger, S Devereux, PM Barr, RR Furman, TJ Kipps, F Cymbalista, C Pocock, P Thornton, F Caligaris-Cappio, T Robak, J Delgado Show all
New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2014
Abstract
BACKGROUND: In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome. METHODS: In this multicenter, open-label, phase 3 study, we randomly assigned 391 patients with relapsed or refractory CLL or SLL to receive daily ibrutinib or the anti-CD20 antibody ofatumumab. The primary end point was the duration of progression-free survival, with the duration of overall survival and the overall response rate as secondary end points. RE..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
Funded by Pharmacyclics and Janssen; RESONATE ClinicalTrials.gov number, NCT01578707.